Peer Review History
| Original SubmissionApril 7, 2021 |
|---|
|
Transfer Alert
This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.
PONE-D-21-11421 Trends in COVID-19 case-fatality rates in Brazilian public hospitals: an analysis based on 398,063 hospital admissions records from 1st March to 3rd October 2020 PLOS ONE Dear Dr. Zimmermann, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 28 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Aleksandar R. Zivkovic Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2) Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 3) In your ethics statement in the Methods section and in the online submission form, please clarify whether all data were fully anonymized before you accessed them. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer #1: This is an interesting paper, and useful as a resource to examine the changing nature of in-hospital fatality for COVID-19 in Brazil. I hope that the authors edit the paper, as it would be a shame to see it go unpublished. There are several major issues with the publication as it currently stands: 1. The paper reports adhering to the STROBE guidelines for observational research, but does not. Some of these issues are minor, such as the title which should properly identify the study as a longitudinal cohort according to STROBE, but some are more major. In particular, the covariates used in the primary analysis are not well described and are very hard to understand. How is ethnicity defined in hospital collections in Brazil? How is this data accessed? What comorbidities were included, how were they identified (ICD codes?), does this leave room for error and which errors if so? I would suggest the authors carefully go through not just the STROBE checklist, but the accompanying papers to ensure that they are indeed meeting the guidelines for reporting. 2. There is no information on how deaths were garnered from the records, which is a major weakness of the research. Were these in-hospital deaths? Does Brazil have a linked hospital/death reporting system? If these are in-hospital deaths, reporting lags may be a large issue - if not, death reporting across regions should be considered as a potential weakness. 3. One hypothesis for the changing hospital CFR in many places is the nature of the pandemic itself. In the UK, hospital CFRs fell from the peak until the second wave, and then increased again. This is potentially due to an overwhelming effect, whereby a large number of COVID-19 cases changes the type of patient who is admitted to hospital, and thus changes the denominator for the in-hospital CFR. While it may be impossible to fully examine the impact of such changes, it is clear from the trends in CFR when stratified by age and ethnicity that there is some impact. It might be useful for this study to look at the hospital CFR for each region over time against the current caseload of that area, although this is an addition that would take some extra work. 4. There is insufficient information in the text about missing data. While routine hospital data is incredibly useful, it is also usually filled with missing fields. While the dataset appears to be impressive, there should be a detailed discussion in the manuscript of how missing data was managed. 5. The statistical analysis is currently not fully described. The method of obtaining smoothed curves should be elucidated. 6. A somewhat minor point, but to me the tables are extremely hard to read. I would suggest having more columns and fewer rows, perhaps breaking each table down by age group. Similarly, the regression outputs are hard to read, especially given that the reference categories have been excluded. 7. While the introduction and discussion are good, I would ask for more information particularly in the introduction about the Brazilian hospital system. For international readers, there is scant detail on how it works - an additional paragraph would be very helpful to understand the context. 8. Currently, the link the authors have provided to their data/code goes to github's main webpage. Probably a typo. Reviewer #2: This article describes the evolution of hospital lethality due to COVID-19 in the public hospital care system in Brazil. The article uses patient health data collected by the Brazilian public social insurance system, which covers more than 300,000 patients, with the indication of the duration of hospitalization and the outcome of the hospitalization. This large dataset allows a precise analysis of the evolution of hospital lethality and the article is of undeniable interest. Some general remarks: 1. Brazil is a very big country and have a very heterogeneous geography. The authors could present in more detail the differences between the different States of Brazil (instead regions). 2. It would be interesting to have indication on the duration of the hospitalization (statistical distribution, relationship with the outcome of the disease, etc.). 3. To study the dynamics and evolution of CFR and to compare rates over time, if we want to exclude known factors related to death (mainly age), we have to standardize on age between weeks: therefore, we have to take into account the evolution of the age structure of patients over time. 4. In several countries a strong correlation between morbidity and case fatality rates has been observed. It would be interesting to have this analysis also for Brazil. And in particular to do it by state, because the differences between regions in the evolution of the disease are sensitive (but as mentioned before, when comparing geographical units, it is necessary to standardize on age). 5. Finally, it should be noted that it is always difficult to compare hospital case fatality rates between countries, because even within areas with comparable health systems (e.g., the EU), these hospital case fatality rates show differences that cannot be explained solely by differences in patient management, but first by the difference between countries in definition, declaration and reporting systems for morbidity and mortality 6. The quality of illustration can be improved. Maps are welcome. Some minor remarks: 1. Why calculate the lethality rate per week, when the calculation can be done per day and then smoothed per week? 2. Line 58, 59. Hospital (or inpatient, or intensive care unit inpatient) fatality rate (not mortality rate) 3. Line 63-71: need to adjust the terminology (death rates, hospital fatality rate, adjusted mortality…). I think that « inpatient case-fatality rate » or « hospital case-fatality rate » is appropriate. 4. Line 142: better “proportion between the number of COVID-19 related admission that evolved to death and the total number of COVID-19 admission in that week”. 5. Line 170-179: all these results by category (age, ethnicity, comorb.) in the hospitalized COVID-19 population must be compared with the proportion of the same category in the global population, and the authors must indicate if the differences are statistically significant. Table 1 must present these results. 6. Line 182-184: Table 1 is mixing different information. I think it must be splitled in various tables. For example, Comorbidity analysis with CFR differences will be very interesting. 7. Line 195-201: Must present morbidity rates and not only morbidity. 8. Line 208-212: comparison of CFR between ethnic group is interesting only if major cause of death (age) in excluded: data must be standardized on age before comparison. Also, size of groups is different: it is needed to present confidence intervals. 9. Line 223-226: Is there a relationship between morbidity and CFR, as observed in other countries? Globally? By region? It is possible that changes in CFR are directly related to morbidity, so the study should be refined by analyzing data on regions (or better on states). 10. Line 235-239: this is very strange. Perhaps the explanations given in the discussion (data quality) could be the subject of an earlier paragraph in the data and methods section. 11. Line 246: there is no indication of the source of the data on the health care system or the criteria used to characterize it ("well-equipped and staffed hospital" is not enough). 12. Line 266: reference needed. 13. Line 336: remark: the same level of CFR was observed in France in second and third wave. Reviewer #3: This is a straightforward epidemiological study of a cohort of nationwide COVID-admissions in Brazil from March to October 2020 analyzing in-hospital mortality and its associated factors. The study has been well planned and executed. The sheer size of the cohort gives the opportunity to examine factors influencing the CFR with a high power. I would wish the authors to clarify only a couple of points: The decrease in CFR is highest and most pronounced in the short term hospitalized group. This raises the question, whether the populations hospitalized in different categories (short term, non-ICU vs. ICU) changed over time. Examining these questions could be important for the interpretation of the time trends shown. In addition, if there are changes in the populations an additional analysis stratified for variables with clear changes over time should be done (or reported if already done). ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Gideon Meyerowitz-Katz Reviewer #2: No Reviewer #3: Yes: Bernd Salzberger, MD [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Trends in COVID-19 case-fatality rates in Brazilian public hospitals: a longitudinal cohort of 398,063 hospital admissions from 1st March to 3rd October 2020 PONE-D-21-11421R1 Dear Dr. Zimmermann, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Aleksandar R. Zivkovic Academic Editor PLOS ONE |
| Formally Accepted |
|
PONE-D-21-11421R1 Trends in COVID-19 case-fatality rates in Brazilian public hospitals: a longitudinal cohort of 398,063 hospital admissions from 1st March to 3rd October 2020 Dear Dr. Zimmermann: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Aleksandar R. Zivkovic Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .